阿法骨化醇对大剂量糖皮质激素治疗肾小球疾病所致的骨质疏松的影响被引量：6

Effect of alfacalcidol on osteoporosis induced by large dose glucocorticoid treatment in glomerulonephritis patients

下载PDF

导出

摘要目的:观察阿法骨化醇联合钙剂对肾脏病患者发生糖皮质激素性骨质疏松的预防作用。方法:28例病人随机分为治疗组16例,阿法骨化醇1μg日一次口服和碳酸钙750 mg日三次口服;对照组12例,碳酸钙750 mg日三次口服。治疗前及以后每3个月检查血清白蛋白、钙、磷、24小时尿蛋白定量、甲状旁腺素,腰椎和股骨颈骨密度,观察6个月。结果:两组患者腰椎和股骨颈骨密度均呈下降趋势,治疗6个月时,治疗组骨密度高于对照组(腰椎0.967±0.105,0.896±0.131,P<0.05;股骨颈1.078±0.124,0.925±0.107,P<0.05),对照组骨密度较治疗前明显下降。结论:阿法骨化醇合用钙剂对预防慢性肾脏病患者发生糖皮质激素性骨质疏松是安全有效的药物。 AIM：To observe the effect of alfacalcidol on osteoporosis induced by large dose glucocorticoid treatment in glomerulonephritis patients.METHODS：28 patients with glomerulonephritis receiving glucocorticoids were divided into two groups randomly.16 patients received calcium carbonate 750 mg three times plus alfacalcidol 1μg one time orally a day（treatment group）,and 12 patients received calcium carbonate 750 mg three times orally a day（control group）.Bone mineral density（BMD） in the lumbar spine（L2-4） and the femoral neck were measured by dual-energy X-ray absorptiometry （DEXA）.Intact parathyroid hormone（iPTH）, serum albumin（ALB）,serum calcium and phosphorus were detected before and 3,6 months after treatment.RESULTS：BMD in the treatment group at the sixth month were higher than control group（lumbar spine 0.967±0.105,0.896±0.131,P〈0.05;femoral neck 1.078±0.124,0.925±0.107,P〈0.05）.BMD in the control group at the sixth month were lower than those before treatment.There were no statistical differences in iPTH,ALB,serum calcium and phosphorus in two groups before and 3, 6 months after therapy.CONCLUSION：Alfacalcidol can decrease loss of bone mass in the lumbar spine and the femoral neck in the glomerulonephritis patients receiving glucocorticoid therapy.

作者于长青王可平杭宏东谢华李龙凯王静

机构地区大连医科大学附属第一医院肾内科

出处《中国临床药理学与治疗学》 CAS CSCD 2010年第4期446-449,共4页 Chinese Journal of Clinical Pharmacology and Therapeutics

关键词阿法骨化醇糖皮质激素肾小球疾病骨密度 Alfacalcidol Glucocorticoid Glomerulonephritis Bone mineral density

分类号 R692 [医药卫生—泌尿科学]

引文网络
相关文献

参考文献13

1Van Staa TP, Lenfkens HG, Abenhaim L, et al. Use of oral eorticosteroids and risk of fracture[J].J Bone Miner Res, 2000, 15(6):993-1000.
2Fujita T, Satomura A, Hidaka M, et al. Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephritic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy[J]. Calcif Tissue Int, 2000, 66 (3): 195-199.
3Yonemura K, Kimura M, Miyaji T, et al. Short- term effect of vitamin K administration on prednisolone-induced loss of bone mineral density in patient with chronic glomerulonephritis[J].Caleif Tissue Int, 2000, 66(2): 123-128.
4Reginster JY, Kuntz D, Verdickt W, et al. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis[J]. Osteoporosi Int, 1999, 9 (1) : 75- 81.
5Peel NFA, Moore DJ, Barrington NA, et al. Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis [J]. Ann Rheum Dis, 1995, 54(10): 801-806.
6van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocortieoid therapy [J]. Arthritis Rheum, 2003, 48(11): 3224- 3229.
7Hong D, Chen HX, Ge RS, et al. The biological roles of extracellular and intracytoplasmic glucocorticoids in skeletal cells[J].J Steroid Biochem Mol Blot, 2008, 111(3):164-170.
8Canalis E, Mazziotti G, Giustina A, et al. Glucocorticoid-induced osteoporosis: pathophysiology and therapy[J]. Osteoporos Int, 2007, 8(10): 1319-28.
9Kim HJ, Zhao H, Kitaura H, et al. Glueoeorticolds suppress bone formation via the osteoclast[J]. J Clin Invest, 2006, 116(8):2152-2160.
10Azuma K, Urano T, Ouchi Y, et al. Glucocorticold-induced gene tripartite motif-containing 63 (TRIM63) promotes differentiation of osteoblastie cells[J].Endocr J,2010, 20(2) :1-8.

二级参考文献34

1万学峰,牛文光,惠艳.糖皮质激素性骨质疏松的治疗进展[J].临床荟萃,2004,19(18):1075-1077. 被引量：9
2张俊,葛宁,黄晓丽,张新军.骨质疏松症的药物治疗评价[J].中国实用内科杂志：临床前沿版,2006,26(2):313-315. 被引量：25
3王义生,胡新永.糖皮质激素性骨质疏松症的防治研究进展[J].河南医学研究,2006,15(2):185-188. 被引量：9
4糖皮质激素性骨质疏松症诊疗指南(讨论稿)[J].中华全科医师杂志,2006,5(8):460-461. 被引量：27
5Hirayama T, Sabokbar A, Athanasou NA. Effect of corticosteroids on human osteoclast formation and activity[ J]. J Endocrinol, 2002,175( 1 ) : 155 - 163.
6Durieux S, Mercadal L, Oreel P, et al. Bone mineral density and fracture prevalence in long-term kidney graft recipients[J] .Transplantation, 2002,74(4) :496 - 500.
7Yood RA, Harrold LR, Fish L, et al. Prevention of glucocorticoid induced osteoporosis [ J]. Arch Intern Med, 2001,161(5) : 1322 - 1327.
8Homik J, Suarez-Mmazor ME, Shea B, et al. Calcium and vitamin D for corticosteroid induced osteoporosis[ J]. Cochrane Database Syst Rev, 2000,10(2) :952 - 957.
9Krieg MA, Seydoux C, Sandini L, et al. Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study [J]. Osteoporosis Int, 2001, 12(2):112- 116.
10Porthouse J, Cockayne S, King C, et al. Randomised controlled trial of supplementation with calcium and cholecalciferol (vitamin D3 ) for prevention of fractures in primary care[J]. BMJ, 2005,330(5) :1003 - 1006.